RT Journal Article
SR Electronic
T1 Super-spreading events initiated the exponential growth phase of COVID-19 with ℛ<sub>0</sub> higher than initially estimated
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.26.20080788
DO 10.1101/2020.04.26.20080788
A1 Kochańczyk, Marek
A1 Grabowski, Frederic
A1 Lipniacki, Tomasz
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.04.26.20080788.abstract
AB The basic reproduction number ℛ0 of the coronavirus disease 2019 has been estimated to range between 2 and 4. Here we used a SEIR model that properly accounts for the distribution of the latent period and, based on empirical estimates of the doubling time in the near-exponential phases of epidemic progression in several locations, we estimated that ℛ0 lies in the range 4.7–11.4. We explained this discrepancy by performing stochastic simulations of model dynamics in a population with a small proportion of super-spreaders. The simulations revealed two-phase dynamics, in which an initial phase of relatively slow epidemic progression diverts to a faster phase upon appearance of infectious super-spreaders. Early estimates obtained for this initial phase may suggest lower ℛ0.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Science Centre (Poland) grant 2018/29/B/NZ2/00668.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There is no human data used in this paper that would require an IRB or ethics committee approvalsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are provided in manuscript and references therein